Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DITPA for Allan-Herndon-Dudley syndrome
ACTRN12611001149954Phase 2Recruiting
- Sponsor
- Zarion Pharmaceuticals
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 3,5-diiodothyropropionic acid in Allan-Herndon-Dudley syndrome (AHDS) (2 arms), sponsored by Zarion Pharmaceuticals. Primary endpoints: Improvement of symptoms and parameters associated with AHDS, Safety and tolerability and 3 more. Started Nov 2011; status: recruiting.
02
Drugs
3,5-diiodothyropropionic acid
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on ACTRN12611001149954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001149954.